SecBot SecBot
DEFA14A ·Filed May 20, 2026

PCRX

Pacira BioSciences, Inc.
MIXED
Impact 6/10
Horizondays Processed6mo ago SEC0001628280-26-036972
Proxy solicitation materials
Actionable Insight ◆ Mixed

The proxy fight outcome is binary and will be decided at the June 9 meeting. Management's strong operating results and buyback program support the incumbent board, but DOMA's activist campaign introduces uncertainty around capital allocation and strategic direction. Watch for proxy advisory firm recommendations (ISS/Glass Lewis) and institutional investor voting patterns in the coming days.

DirectionMixed
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$23.48
T+0 close · May 20, 2026 · via day close
Latest settled
−1.02%
T+60 · $23.24
Vs SPY
−5.32%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 21 $23.48entry
  2. T+1 · 6mo ago −0.55%α −1.00% · $23.35
  3. T+5 · 6mo ago −1.11%α −2.96% · $23.22
  4. T+20 · 5mo ago −3.24%α −3.57% · $22.72
  5. T+60 · 3mo ago −1.02%α −5.32% · $23.24

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pacira BioSciences filed additional definitive proxy soliciting materials (DEFA14A) urging stockholders to vote FOR management's director nominees on the BLUE proxy card at the June 9, 2026 annual meeting, directly countering activist DOMA Perpetual Capital Management's dissident slate. The filing highlights record 2025 financial results ($726.4M revenue, 79.4% GAAP gross margins), strong Q1 2026 momentum across all commercial products, a $300M buyback program with $200M returned, and a favorable EXPAREL patent settlement securing exclusivity through 2030. Management characterizes DOMA's campaign as seeking to replace the board with unqualified candidates, cut R&D, and pursue a fire sale.

Key Financial Metrics

Vote
director election
Meeting
2026-06-09
Seats Contested
3

Key Facts

  • Annual meeting scheduled June 9, 2026; record date April 22, 2026
  • Activist DOMA Perpetual Capital Management nominating three director candidates
  • Pacira achieved record 2025 total revenue of $726.4M and GAAP gross margins of 79.4%
  • Q1 2026: EXPAREL revenue $143.3M (+5% YoY), ZILRETTA $26.8M (+15%), iovera $6.2M (+21%)
  • $300M share repurchase authorized April 2025; $200M returned to stockholders through March 31, 2026
  • Favorable volume-limited EXPAREL patent settlement secures exclusivity through 2030
  • Board would be 89% independent with ~4.6 year average tenure after annual meeting
  • Goldman Sachs acting as financial advisor; Perkins Coie as legal counsel

Financial Impact

Record 2025 revenue of $726.4M; Q1 2026 EXPAREL revenue $143.3M (+5% YoY); $200M returned via buyback since April 2025

revenuegross marginshare repurchasepatent exclusivity

Risk Factors

  • Activist DOMA could win board seats, leading to strategic shift, cost cuts, or sale process
  • Proxy contest may distract management from commercial execution and pipeline advancement
  • Patent settlement terms (volume-limited) could constrain EXPAREL growth trajectory
  • Heavy reliance on EXPAREL revenue concentration remains a key business risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001628280-26-036972
Document: 0001628280-26-036972-index-headers.html0001628280-26-036972
Document: 0001628280-26-036972-index.html0001628280-26-036972
Document: 0001628280-26-036972.txt0001628280-26-036972

Track record

29 reports on PCRX

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
  2. Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  3. Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
  5. Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
  6. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  7. Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  8. Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  9. Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
  10. Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 20, 2026